Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
Ramírez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ. Ramírez J, et al. Among authors: undevia s. Pharmacogenet Genomics. 2014 Feb;24(2):129-32. doi: 10.1097/FPC.0000000000000023. Pharmacogenet Genomics. 2014. PMID: 24300566 Free PMC article.
Pharmacokinetic variability of anticancer agents.
Undevia SD, Gomez-Abuin G, Ratain MJ. Undevia SD, et al. Nat Rev Cancer. 2005 Jun;5(6):447-58. doi: 10.1038/nrc1629. Nat Rev Cancer. 2005. PMID: 15928675 Review.
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. Yong WP, et al. Eur J Cancer. 2009 Jul;45(11):1904-8. doi: 10.1016/j.ejca.2009.04.032. Epub 2009 May 21. Eur J Cancer. 2009. PMID: 19464879 Free PMC article.
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Innocenti F, et al. Among authors: undevia s. J Clin Oncol. 2014 Aug 1;32(22):2328-34. doi: 10.1200/JCO.2014.55.2307. Epub 2014 Jun 23. J Clin Oncol. 2014. PMID: 24958824 Free PMC article. Clinical Trial.
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. Stock W, et al. Among authors: undevia sd. Invest New Drugs. 2008 Aug;26(4):331-8. doi: 10.1007/s10637-008-9129-0. Epub 2008 Apr 19. Invest New Drugs. 2008. PMID: 18425419 Free PMC article. Clinical Trial.
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. O'Donnell PH, et al. Among authors: undevia sd. Leuk Lymphoma. 2010 Dec;51(12):2240-9. doi: 10.3109/10428194.2010.520773. Epub 2010 Oct 4. Leuk Lymphoma. 2010. PMID: 20919852 Free PMC article. Clinical Trial.
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. Ratain MJ, et al. Among authors: undevia sd. Invest New Drugs. 2015 Aug;33(4):901-10. doi: 10.1007/s10637-015-0247-1. Epub 2015 May 8. Invest New Drugs. 2015. PMID: 25947566 Clinical Trial.
32 results